Polynovo Ltd

MFJ

Company Profile

  • Business description

    Polynovo earns most of its revenue from US sales of its NovoSorb Biodegradable Temporizing Matrix, or NovoSorb BTM. The product is a patented biodegradable synthetic scaffold to support the regeneration of the dermis when lost through surgery, trauma, burns, or other causes of tissue loss. Once the product is applied to a wound, it takes a few weeks for the dermal layer to fully integrate within the polymer scaffold before a clinician can delaminate the outer layer. A small wound would then close either naturally or with a dressing, while a larger wound would close through a split-skin graft or alternative product such as Avita’s RECELL. NovoSorb BTM then slowly degrades to harmless byproducts which are fully absorbed in roughly 18 months.

  • Contact

    320 Lorimer Street
    Unit 2
    Port MelbourneVIC3207
    AUS

    T: +61 386814050

    https://www.polynovo.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Medical Devices

    Fiscal Year End

    30 June 2025

    Employees

    8

Stocks News & Analysis

stocks

Microsoft earnings: Strength in cloud, guidance mixed

We think investors should be on board when Azure accelerates in the third quarter.
stocks

Chart of the week: Small caps lagging

This week's chart of the week comes from Morningstar's Market Strategist's take on small caps
stocks

An impending merger just raised our fair value for this ASX retail giant

The deal is set to deliver enhanced scale, cost savings and new synergies.  

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,379.7042.40-0.50%
CAC 407,409.1158.740.80%
DAX 4019,254.97177.430.93%
Dow JONES (US)42,052.19288.730.69%
FTSE 1008,177.1567.050.83%
HKSE20,506.43189.100.93%
NASDAQ18,239.92144.770.80%
Nikkei 22538,053.671,027.58-2.63%
NZX 50 Index12,559.2879.62-0.63%
S&P 5005,728.8023.350.41%
S&P/ASX 2008,118.8041.20-0.50%
SSE Composite Index3,272.017.81-0.24%

Market Movers